Contains Nonbinding Recommendations

Draft Guidance on Ivacaftor

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Ivacaftor

Dosage Form; Route: Granule; oral

Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in vivo
   Strength: 75 mg/packet at a dose of 150 mg (2x75 mg/packet)
   Subjects: Healthy males and females (nonpregnant), general population
   Comments: Female subjects should not be pregnant or lactating, and if applicable, should practice abstinence or contraception during the study.

2. Type of study: Fed
   Design: Single-dose, two-way crossover in vivo
   Strength: 75 mg/packet at a dose of 150 mg (2x75 mg/packet)
   Subjects: Healthy males and females (nonpregnant), general population
   Comments: See comments above.

Analytes to measure (in appropriate biological fluid): Ivacaftor in plasma

Bioequivalence based on (90% CI): Ivacaftor

Waiver request of in vivo testing: 50 mg/packet based on (i) acceptable bioequivalence studies on the 75 mg/Packet strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application.